Dr. Raffaele has appeared on National Public Radio and the local news broadcasts of NBC and ABC in New York, and has been quoted in The New York Times, Vogue, Elle, New York Post, and France’s Le Nouvel Observateur.

Our Team

We’ve assembed a team of smart, passionate individuals
who bring unique skills to the table.

Joseph M. Raffaele, MD

Founder and Chief Medical Officer

Joseph Raffaele received his BA in philosophy from Princeton University and his MD from Hahnemann University Medical School in 1989. Dr. Raffaele did his residency at The New York Hospital/Cornell University Medical Center and was formerly a clinical assistant professor of medicine at Dartmouth Medical School while in practice at the Hitchcock Clinic. Dr. Raffaele is a member of the American College of Physicians, is board certified in internal medicine, and is a diplomat of the American Board of Age management Medicine.

In 1995 Dr. Raffaele began researching and developing a scientifically-based treatment program and co-founded PhysioAge Medical Group. Since 1997 Dr. Raffaele has been focused on age management medicine and biomarkers of aging. As CEO of PhysioAge, Dr. Raffaele developed the combination of biomarkers currently in use and has worked with Dr. Kumm to develop PhysioAge formula.

Jerry Fortunato, MBA, PMP


Jerry Fortunato received his BS in Finance from Rutgers University and his MBA from Rutgers Business School. He has been a Project Management Professional since 2003.

Jerry co-founded PhysioAge with Dr. Raffaele in 2008, where he is responsible for managing most business operations including marketing, sales, product management and technical support.

J. Daniel Powell

Chief Technology Officer

Dan Powell has over fifteen years of startup, management, architecture, and development experience. He has spent most of his career solving large-scale data problems, focusing on high-volume data processing, web and mobile systems. Dan also has over 20 years of experience in the open source community including contributing to the development of the Linux kernel for DEC Alpha processors and the development of the Stampede Linux distribution. He studied mathematics and chemistry at North Carolina State University.

Jennifer Braun, MPH, PA

Director of Clinical Content

Jennifer Braun has been in clinical practice within the field of healthy aging for 10 years with a background in primary care and clinical research. She earned an MPH from UCLA and an MS in Physician Assistant Studies from Stony Brook University.

Jennifer joined PhysioAge in 2017 as a clinical advisor, supporting product management and development, as well as site support. She is also a clinical provider within Raffaele Medical where she develops customized treatment programs for her patients designed to achieve optimal health.

Michael B. Fossel, MD, PhD

Advisory Board

Michael Fossel received a PhD and MD at Stanford, where he had an NSF Fellowship, taught for several years, and studied aging and progeria. He was a Clinical Professor of Medicine at Michigan State University for almost three decades and currently teaches the Biology of Aging at Grand Valley State University.

He founded the Journal of Anti-Aging Medicine (now Rejuvenation Research), and has published several dozen articles in JAMA, In Vivo, and other journals.

In 1996, he published Reversing Human Aging, explaining the telomere theory of aging, which was reviewed favorably in Scientific American and has been translated in 6 languages. He has appeared on Good Morning America, ABC 20/20, NBC Extra, Fox Network, CNN, BBC, Discovery Channel, and regularly on NPR.

His magisterial textbook, Cells, Aging, and Human Disease, was published in 2004 by Oxford University. With over four thousand references, it reviews the entire fields of telomere biology and cell senescence as they apply to human clinical disease as well as the potential for treating these diseases using telomerase therapy.

His newest book, The Telomerase Revolution, (which is already selling well in pre-orders on Amazon) will be published in October 2015 and explains the aging process, age-related diseases, and the upcoming human clinical trials of telomerase therapy. His new biotech company, Telocyte, is aimed at curing Alzheimer’s disease.